Drugs / DS003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02877979 | Nov 2015 → Aug 2016 | HIV infectious disease | International Partnership for Microbicides, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02877979 ↗ |
| Known as | BMS-599793 | “The entry inhibitor DS003 (BMS-599793): a BMS-806 analogue, provides superior activity as a pre-exposure prophylaxis candidate.” PMID 34101626 ↗ Oct 2021 |
| Action | Inhibit | “DS003 inhibits HIV-1 infection by binding to or near the CD4+ binding site of gp120, preventing CD4+-induced conformational change essential for viral fusion.” PMID 34101626 ↗ Oct 2021 |